xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

487

Orlandi et al.

(Continues)

TABLE X-16 Evidence for aspirin intolerance as a contributing factor for CRSwNP Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Rajan 1521 2015 2 Systematic review with meta-analysis 7 groups based on disease (asthma, NP or CRS, or both) Prevalence study Prevalence of AERD in patients with CRSwNP is 9.7%. Stevens 198 2017 3 Large retrospective prevalence study AERD CRSwNP and asthma CRSwNP without asthma Prevalence study and clinical characteristics of CRSwNP Patients with AERD have more severe CRSwNP phenotype. Mendelsohn 1530 2011 3 Large retrospective cohort study Patients undergoing ESS for NP (n = 549) Recurrence (measured by Kaplan Meier curves) Revision rates are significantly higher in AERD. Kowalski 1519 2019 5 Nonsystematic review/expert opinion Update on pathophysiology, subtypes and treatment options in AERD. Cahill 1524 2017 5 Nonsystematic review/expert opinion Update on molecular mechanisms of AERD. Laidlaw 1518 2016 5 Nonsystematic review/expert opinion Update on molecular mechanisms and pathophysiology of AERD.

Chang 1532 2014 5 Bench research No significant association between the FABP1 polymorphisms and AERD.